[Preliminary assessment of the effectiveness of L-dopa with prolonged action (Medidopa retard) as compared to conventional L-dopa preparation].
The therapeutic effectiveness of a L-DOPA preparation of sustained action was established in 9 patients with parkinsonism on the basis of a neurological parkinsonism scale and Northwestern University Disability Scale. The investigations were carried out by the method of cross test with conventional L-DOPA preparation (Larodopa). In these investigations no higher effectiveness of the retard form was shown. Side effects during administration of the retard form were more frequent and more intense than during administration of the conventional drug.
D000368:Aged; D003692:Delayed-Action Preparations; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*
D003692:Delayed-Action Preparations; D007980:Levodopa
Wstepna ocena skuteczności preparatu L-dopa o przedłuzonym działaniu (medidopa retard) w porównaniu z konwencjonalnym preparatem L-dopa.